KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBIT Margin (2016 - 2026)

NovoCure's EBIT Margin history spans 13 years, with the latest figure at 38.73% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 1430.0% to 38.73% in Q1 2026 year-over-year; TTM through Mar 2026 was 27.19%, a 35.0% decrease, with the full-year FY2025 number at 23.47%, up 470.0% from a year prior.
  • EBIT Margin hit 38.73% in Q1 2026 for NovoCure, down from 23.17% in the prior quarter.
  • Over the last five years, EBIT Margin for NVCR hit a ceiling of 0.59% in Q1 2022 and a floor of 49.71% in Q2 2023.
  • Historically, EBIT Margin has averaged 29.19% across 5 years, with a median of 24.89% in 2025.
  • Biggest five-year swings in EBIT Margin: tumbled -4872bps in 2023 and later skyrocketed 2738bps in 2024.
  • Tracing NVCR's EBIT Margin over 5 years: stood at 33.46% in 2022, then dropped by -16bps to 38.66% in 2023, then fell by -2bps to 39.25% in 2024, then surged by 41bps to 23.17% in 2025, then plummeted by -67bps to 38.73% in 2026.
  • Business Quant data shows EBIT Margin for NVCR at 38.73% in Q1 2026, 23.17% in Q4 2025, and 21.54% in Q3 2025.